Moderate monovision vs mini-monovision with a small-aperture intraocular lens: visual outcomes and patient satisfaction

Session Details

Session Title: New IOL Optic Design

Session Date/Time: Tuesday 17/09/2019 | 16:30-18:00

Paper Time: 17:25

Venue: Free Paper Forum: Podium 1

First Author: : B.Soares AUSTRALIA

Co Author(s): :    J. Beltz                             

Abstract Details

Purpose:

To evaluate visual outcomes and satisfaction of patients having bilateral cataract surgery with either bilateral aspheric monofocal IOLs with a moderate monovision target or unilateral implantation of a monofocal IOL and contralateral implantation of a small-aperture IOL with a mini-monovision target.

Setting:

Prospective, randomized, single-site study

Methods:

Forty patients randomized into 2 groups. Group 1 treated bilaterally with aspheric monofocal IOLs targeting emmetropia and -1.25 D in dominant and non-dominant eyes respectively. Group 2 implanted with an aspheric monofocal IOL in the dominant eye targeting emmetropia and an IC-8 IOL in the non-dominant eye targeting -0.75 D. Monocular and binocular uncorrected near, intermediate and distance visual acuity (UNVA, UIVA, UDVA) are presented in decimal. Manifest refraction spherical equivalent (MRSE), symptoms (Scale: 0=none, 5=very severe) and satisfaction (Scale: 1=very dissatisfied, 5=very satisfied) were also evaluated. We present one-month post-operative results of 36 patients.

Results:

Mean monocular UCDVA in the non-dominant eye was 0.37 ± 0.19 in Group 1 (N=20) and 0.59 ± 0.20 for Group 2 (N=16). Mean monocular UCIVA and UCNVA were comparable. Binocularly, Group 1 achieved 0.97 ± 0.18, 0.80 ± 0.26, and 0.64 ± 0.24 for UCDVA, UCIVA, and UCNVA. Group 2, achieved 0.99 ± 0.09, 0.88 ± 0.30 and 0.60 ± 0.22 for binocular UCDVA, UCIVA, and UCNVA. Mean MRSE in the non-dominant eye was -1.58 D ± 0.54 and -1.16 D ± 0.72 for Group 1 and 2, respectively. Satisfaction and symptoms scores were comparable between groups.

Conclusions:

Early results show mini-monovision using the IC-8 IOL achieves comparable near and intermediate vision, comparable symptoms and satisfaction, and superior distance vision to moderate monovision with less myopia in the non-dominant eye.

Financial Disclosure:

research is funded, fully or partially, by a company producing, developing or supplying the product or procedure presented